Loading...
•
Sep 30, 2025
AIM ImmunoTech Q3 2025 Earnings Report
AIM ImmunoTech's Q3 2025 earnings report was released, detailing financial results and a business update.
Key Takeaways
AIM ImmunoTech reported a net loss of $5.2 million for the third quarter of 2025, an improvement from the $6.2 million net loss in the prior year's quarter. The company's cash and cash equivalents stood at $25.2 million, providing liquidity for ongoing operations and clinical trials, particularly the DURIPANC trial for pancreatic cancer.
Net loss for Q3 2025 improved to $5.2 million from $6.2 million in Q3 2024.
Cash and cash equivalents were $25.2 million as of September 30, 2025.
Research and development expenses decreased to $3.0 million from $3.8 million in the prior year.
General and administrative expenses increased to $2.2 million from $2.0 million in the prior year.
Forward Guidance
AIM ImmunoTech is focused on advancing Ampligen towards FDA approval for pancreatic cancer, with a year-end update on the DURIPANC trial expected by the end of the current quarter. The company expresses confidence in delivering long-term value through its ongoing clinical, manufacturing, and regulatory efforts.
Positive Outlook
- Heavy focus on moving Ampligen towards FDA approval for pancreatic cancer.
- Positive mid-year safety and efficacy data reported from the DURIPANC clinical trial.
- Anticipated year-end update for the DURIPANC trial by the end of the current quarter.
- Building a strong foundation for long-term value delivery.
- Ongoing clinical, manufacturing, and regulatory execution.
Challenges Ahead
- Data, pre-clinical success, and clinical success to date do not guarantee Ampligen's approval for any indication.
- Involves a number of risks and uncertainties as identified in SEC filings.
- Investors are cautioned not to place undue reliance on forward-looking statements.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...